Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

You may be eligible if

• Histologically confirmed endometrial cancer including 1 of the following subtypes:
• * Clear cell carcinoma
• * Serous papillary carcinoma
• * Endometrioid adenocarcinoma
• Stage III or IV disease
• * Positive adnexa
• * Metastases to serosa, bowel mucosa, abdomen
• * Positive pelvic or paraaortic nodes
• * Positive pelvic washings or vaginal involvement within the radiation port
• Tumor must be surgically reduced to 2 cm or less within 8 weeks of study entry
• * Must have had a hysterectomy and bilateral salpingo oophorectomy
• No recurrent disease
• No distant metastases outside of abdominopelvic area, including:
• * Parenchymal liver metastases
• * Lung metastases
• * Positive inguinal lymph nodes
• * Positive supraclavicular nodes
• * Pleural effusion with malignant cytology
• Performance status - GOG 0-2
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• SGOT and alkaline phosphatase no greater than 3 times ULN
• Creatinine no greater than ULN
• Cardiac ejection fraction greater than 50%
• No other prior or concurrent malignancy within the past 5 years except nonmelanoma skin cancer
• No prior chemotherapy
• No prior pelvic or abdominal radiotherapy
• No prior radiotherapy for other prior malignancy